ORGANIZATION

FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label

September 13, 2011
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) has drafted a position paper presenting its basic policy on the providing of information on drugs used off-label. The paper specifies that drug marketers are allowed to provide such information at…

To read the full story

ORGANIZATION

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…

By Ken Yoshino

As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…